Nanobiotix (NBTXR3) Lung Cancer Trial Data Presented at ESTRO

Nanobiotix (NBTXR3) presented early data from its lung cancer clinical trial at ESTRO. The presentation included initial results, highlighting a specific treatment's potential effectiveness in target populations. While specific quantitative results were not disclosed, the data could influence investor sentiment and expectations regarding upcoming FDA approvals. This event is significant for NBTXR3 as it may impact the company's market position and future funding opportunities in oncology.